SCHEMBL21443363

SCHEMBL21443363

C=C1N(C)C(=O)c2c(ncn2CC(=O)Nc2nnc(CCCCc3nnc(NC(=O)Cn4cnc5c4c(=O)n(C)c(=O)n5C)s3)s2)N1C

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.61
▸ RXFP1 Q9HBX9 7/20 0.57
▸ ALDH1A1 P00352 2/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ MAPT P10636 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ PORCN Q9H237 1/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ TRPA1 O75762 1/20 0.46
▸ TP53 P04637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15727746 0.89 HSD17B10 (0.75) HSD17B10RXFP1ALDH1A1CYP2C9HPGD
SCHEMBL10113960 0.78 HSD17B10 (0.72) HSD17B10RXFP1ALDH1A1CYP2C9HPGD
SCHEMBL17486884 0.77 ADORA2B (0.58) RXFP1ALDH1A1MAPTTSHR
SCHEMBL17486881 0.77 ADORA2B (0.60) RXFP1ALDH1A1MAPTTSHR
SCHEMBL19499803 0.77 ADORA2B (0.60) RXFP1ALDH1A1MAPTTSHR
SCHEMBL19499801 0.77 ADORA2B (0.60) RXFP1ALDH1A1MAPTTSHR
SCHEMBL19677779 0.75 ADORA2B (0.49) RXFP1ALDH1A1MAPT
SCHEMBL17200781 0.74 RXFP1 (0.68) HSD17B10RXFP1ALDH1A1CYP2C9HPGD
SCHEMBL17486888 0.73 ADORA2B (0.51) RXFP1ALDH1A1MAPT
SCHEMBL18166765 0.73 HSD17B10 (0.78) HSD17B10RXFP1ALDH1A1CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2922832-B1 GLUTAMINASE INHIBITORS AND METHODS OF USE AGIOS PHARMACEUTICALS INC (US) 2019-10-09 — — EP disclosed
Send feedback